Kenna Anderes of Pfizer Global RandD, Michael Shi of Novartis and Joseph Paul Eder of AstraZeneca to give featured presentations
Released on: November 9, 2007, 9:12 am
Press Release Author: GTCbio
Industry: Pharmaceuticals
Press Release Summary: Kenna Anderes of Pfizer Global R&D, Michael Shi of Novartis and Joseph Paul Eder of AstraZeneca to give featured presentations at Oncology Biomarkers: From Discovery to Validation conference on January 14-15, 2008.
Press Release Body: MONROVIA, CA – Kenna Anderes, Director of Oncology Biomarkers at Pfizer Global Research & Development, Michael Shi, Director and Biomarker Project Leader of Exploratory Oncology Development at Novartis Pharmaceutical Corporation and Joseph Paul Eder, Senior Director of Oncology Clinical Research Discovery Medicine at AstraZeneca will give featured presentations at GTCbio’s Oncology Biomarkers: From Discovery to Validation conference on January 14-15, 2008 in San Francisco, CA.
Dr. Anderes will present on Pfizer’s emphasis on imaging biomarkers for oncology programs. Pfizer considers oncology pharmaceuticals and therapeutics to be a top priority, and focuses on biomarkers in their clinical applications and drug development.
Dr. Shi will present on biomarker application in oncology clinical development. He will discuss the application of biomarkers to address key challenges and opportunities in developing novel targeted cancer therapeutics. The main challenges in cancer therapeutics and treatment are to verify the impact of novel drugs on targets/pathways by monitoring pharmacodynamic biomarkers, to evaluate molecular response as an early clinical efficacy read-out, to increase drug development predictability and to give the right drug to the right patients at the optimal dose.
Dr. Eder will discuss biomarkers for clinical decisions in phase I and II trials at AstraZeneca. AstraZeneca repeatedly employs biomarkers in early and late stages of their clinical trials and views their role as critical in cancer drug development.
The Oncology Biomarkers: From Discovery to Validation conference features presentations on future methods and technologies for oncology biomarker discovery and validation, challenges to clinical translation of biomarkers, clinical application and development of oncology biomarkers and enabling biomarkers in cancer drug development. For more information, visit www.gtcbio.com.
ABOUT GTCbio
GTCbio organizes conferences specifically for the biomedical and biopharmaceutical industries. Our goal is to facilitate the exchange of biopharmaceutical and biomedical intelligence between industry leaders, academic and government organizations, and the financial community.
GTCbio is a subsidiary of Global Technology Community, LLC, a privately held company founded in 2002.
2012
